Literature DB >> 2986299

Distribution and possible spread of human T-cell leukaemia virus type I in human communities in the northern and eastern Transvaal.

M C Botha, M Jones, W A de Klerk, N Yamamoto.   

Abstract

The prevalence of serum antibodies which probably indicate infection with a human T-cell leukaemia virus type I was determined among random population samples of more than 100 healthy black individuals in several localities in Transvaal. The percentage of seropositive subjects increases northwards and eastwards, where geoclimatic conditions are similar to those of endemic areas elsewhere in the world. The comparatively higher prevalence among females in the Kruger National Park suggests that this is predominantly a sexually transmitted disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986299

Source DB:  PubMed          Journal:  S Afr Med J


  4 in total

1.  Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces.

Authors:  C R Roberts; D R Fipps; J F Brundage; S E Wright; M Goldenbaum; S S Alexander; D S Burke
Journal:  Am J Public Health       Date:  1992-01       Impact factor: 9.308

2.  Seroepidemiology of HTLV-I in relation to that of HIV-1 in the Gauteng region, South Africa, using dried blood spots on filter papers.

Authors:  M B Taylor; S P Parker; H H Crewe-Brown; J McIntyre; W D Cubitt
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

3.  A seroepidemiologic survey of human T-cell lymphotropic virus type I in two Hawaiian hematologic-oncologic practices.

Authors:  J T Kimata; S A Kaneshiro; D W Kwock; S Nakamura; M M Kaneshiro; J M Nakamura
Journal:  West J Med       Date:  1989-03

Review 4.  Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa.

Authors:  James M Fox; Nora Mutalima; Elizabeth Molyneux; Lucy M Carpenter; Graham P Taylor; Martin Bland; Robert Newton; Fabiola Martin
Journal:  Trop Med Int Health       Date:  2016-02-03       Impact factor: 2.622

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.